SE449105B - 13-/1-oxyl-2,2,6,6-tetrametylpiperyldenyl-4/-rubomycinhydrazon hydroklorid samt forfarande for dess framstellning - Google Patents
13-/1-oxyl-2,2,6,6-tetrametylpiperyldenyl-4/-rubomycinhydrazon hydroklorid samt forfarande for dess framstellningInfo
- Publication number
- SE449105B SE449105B SE8006901A SE8006901A SE449105B SE 449105 B SE449105 B SE 449105B SE 8006901 A SE8006901 A SE 8006901A SE 8006901 A SE8006901 A SE 8006901A SE 449105 B SE449105 B SE 449105B
- Authority
- SE
- Sweden
- Prior art keywords
- rubomycin
- compound
- oxyl
- hydrazone
- hydrochloride
- Prior art date
Links
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 title claims description 12
- 238000000034 method Methods 0.000 title claims description 10
- 238000002360 preparation method Methods 0.000 title claims description 4
- 150000007857 hydrazones Chemical class 0.000 title description 2
- GUGHGUXZJWAIAS-QQYBVWGSSA-N Daunorubicin hydrochloride Chemical group Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 GUGHGUXZJWAIAS-QQYBVWGSSA-N 0.000 claims description 28
- 229930191933 Rubomycin Natural products 0.000 claims description 26
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- -1 hydrazone hydrochloride Chemical class 0.000 claims description 7
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 6
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims description 6
- 230000005414 paramagnetic center Effects 0.000 claims description 5
- 239000007795 chemical reaction product Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000002244 precipitate Substances 0.000 claims description 4
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 239000013256 coordination polymer Substances 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 56
- 229960000641 zorubicin Drugs 0.000 description 15
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 15
- 230000000259 anti-tumor effect Effects 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 208000032839 leukemia Diseases 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- 231100000419 toxicity Toxicity 0.000 description 7
- 230000001988 toxicity Effects 0.000 description 7
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 6
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical class O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 6
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 6
- 229960000975 daunorubicin Drugs 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 3
- 230000007665 chronic toxicity Effects 0.000 description 3
- 231100000160 chronic toxicity Toxicity 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000001451 cardiotoxic effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- GYPCWHHQAVLMKO-XXKQIVDLSA-N (7s,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-[(e)-n-[(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-ylidene)amino]-c-methylcarbonimidoyl]-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical group Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\N=C1CC(C)(C)N(O)C(C)(C)C1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 GYPCWHHQAVLMKO-XXKQIVDLSA-N 0.000 description 1
- 241000194106 Bacillus mycoides Species 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- 238000004435 EPR spectroscopy Methods 0.000 description 1
- 208000000526 Experimental Leukemia Diseases 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- WARCRYXKINZHGQ-UHFFFAOYSA-N benzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1 WARCRYXKINZHGQ-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 231100000457 cardiotoxic Toxicity 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 230000007681 cardiovascular toxicity Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- SIHHLZPXQLFPMC-UHFFFAOYSA-N chloroform;methanol;hydrate Chemical compound O.OC.ClC(Cl)Cl SIHHLZPXQLFPMC-UHFFFAOYSA-N 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001362 electron spin resonance spectrum Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU802893526A RU977462C (ru) | 1980-03-24 | 1980-03-24 | 13-(1-оксил-2,2,6,6-тетраметилпиперилиденил-4)гидразон рубомицина хлоргидрат с парамагнитным центром, проявляющий противоопухолевую активность, и способ его получения |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE8006901L SE8006901L (sv) | 1981-09-25 |
| SE449105B true SE449105B (sv) | 1987-04-06 |
Family
ID=20882488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE8006901A SE449105B (sv) | 1980-03-24 | 1980-10-02 | 13-/1-oxyl-2,2,6,6-tetrametylpiperyldenyl-4/-rubomycinhydrazon hydroklorid samt forfarande for dess framstellning |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US4332934A (enExample) |
| JP (1) | JPS56133298A (enExample) |
| DE (1) | DE3037884C2 (enExample) |
| FR (1) | FR2478633A1 (enExample) |
| GB (1) | GB2072658B (enExample) |
| IT (1) | IT1134110B (enExample) |
| NL (1) | NL182882C (enExample) |
| RU (1) | RU977462C (enExample) |
| SE (1) | SE449105B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050003008A1 (en) * | 1997-09-23 | 2005-01-06 | Natalya Rapoport | Method of in vivo drug targeting to solid tumors via acoustically triggered drug delivery in polymeric micelles |
| US7910607B2 (en) * | 2006-03-10 | 2011-03-22 | The Trustees Of California State University | Nitroxide free radical synergized antineoplastic agents |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2235103A1 (en) * | 1973-06-29 | 1975-01-24 | Commissariat Energie Atomique | Marked nitroxide derivatives of saccharides - by reaction of acid nitroxide with halogenated saccharides |
| GB1469430A (en) | 1974-12-24 | 1977-04-06 | Farmaceutici Italia | Daunomycin derivatives |
| US4112217A (en) * | 1977-09-02 | 1978-09-05 | Sri International | Bis-hydrazones of daunomycin and adriamycin |
-
1980
- 1980-03-24 RU SU802893526A patent/RU977462C/ru active
- 1980-10-02 SE SE8006901A patent/SE449105B/sv not_active IP Right Cessation
- 1980-10-02 US US06/192,964 patent/US4332934A/en not_active Expired - Lifetime
- 1980-10-07 DE DE3037884A patent/DE3037884C2/de not_active Expired
- 1980-10-07 GB GB8032334A patent/GB2072658B/en not_active Expired
- 1980-10-07 NL NLAANVRAGE8005543,A patent/NL182882C/xx not_active IP Right Cessation
- 1980-10-22 FR FR8022569A patent/FR2478633A1/fr active Granted
- 1980-10-30 IT IT25669/80A patent/IT1134110B/it active
-
1981
- 1981-01-08 JP JP158681A patent/JPS56133298A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| RU977462C (ru) | 1995-06-27 |
| DE3037884C2 (de) | 1983-12-29 |
| GB2072658B (en) | 1983-11-02 |
| NL182882B (nl) | 1988-01-04 |
| DE3037884A1 (de) | 1981-10-01 |
| JPS6334879B2 (enExample) | 1988-07-12 |
| IT8025669A0 (it) | 1980-10-30 |
| FR2478633A1 (fr) | 1981-09-25 |
| NL8005543A (nl) | 1981-10-16 |
| FR2478633B1 (enExample) | 1983-07-22 |
| GB2072658A (en) | 1981-10-07 |
| US4332934A (en) | 1982-06-01 |
| IT1134110B (it) | 1986-07-24 |
| NL182882C (nl) | 1988-06-01 |
| SE8006901L (sv) | 1981-09-25 |
| JPS56133298A (en) | 1981-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Deutsch et al. | Synthesis of congeners and prodrugs. 3. Water-soluble prodrugs of taxol with potent antitumor activity | |
| Makarieva et al. | Varacin and Three New Marine Antimicrobial Polysulfides from the Far-Eastern Ascidian Polycitorsp. | |
| DE69121334T2 (de) | DC-89-Derivate als Antitumor-Wirkstoffe | |
| EP0313874B1 (en) | Disulfur analogs of LL-E33288 antitumor agents | |
| EP0537575A1 (en) | Hydrobromide of DC-89 derivative having antitumor activity | |
| DK146542B (da) | Analogifremgangsmaade til fremstilling af daunosaminylanthracyclioner | |
| KR900008676B1 (ko) | 항균성 9-데옥소-9a-알릴 및 프로파길-9a-아자-9a-호모에리트로마이신 A유도체 | |
| SU1054352A1 (ru) | N-гликозиловые производные даунорубицина,про вл ющие антибиотическую активность | |
| SE449105B (sv) | 13-/1-oxyl-2,2,6,6-tetrametylpiperyldenyl-4/-rubomycinhydrazon hydroklorid samt forfarande for dess framstellning | |
| SU1020004A3 (ru) | Способ получени производных олеандомицина | |
| CS198280B2 (en) | Method of producing anthracycline glycosides | |
| US4130648A (en) | 5-Fluorouracil derivatives and antitumor preparations containing the same | |
| EP0451753A1 (de) | Im Ethylenteil substituierte Phenyl-alkylethylendiamin-Platin (II oder IV)-Derivate und Phenylalkyl-ethylendiamine | |
| RU2255089C1 (ru) | Производные гликозидов индоло[2,3-а]пирроло[3,4-с]карбазол-5,7-дионов, обладающие цитотоксической и противоопухолевой активностью | |
| DE69626624T2 (de) | Medikamente gegen trhombocytopenie | |
| SU1301831A1 (ru) | 7-Замещенные 9 @ -метоксимитозана,обладающие противоопухолевой активностью | |
| JPH10502088A (ja) | ブレフェルジンａの新しい誘導体およびがん治療におけるそれらの有用性 | |
| JPH06199749A (ja) | Ｎ−メチルデアセチルコルヒセインアミド誘導体 | |
| JPH04264092A (ja) | シクロトリホスファゼンのｎ，ｏスピロ環状誘導体とその製法および用途 | |
| EP0131285A1 (en) | Enamine derivatives of daunorubicin and adriamycine and pharmaceutical compositions containing them | |
| JPS6129952B2 (enExample) | ||
| EP0191375A2 (en) | 7-n-aminomethylenemitomycin derivatives, process for production thereof and anti-tumor composition | |
| KR0136447B1 (ko) | 폴리오젤루스 속 [Polyozellus multiplex] 균주가 생산하는 신규 항암 활성물질 폴리오젤린 및 그 제조 방법 | |
| EP0071374A1 (en) | Nitrosourea derivatives having anti-tumour and anti-bacterial activity | |
| EP0186807A2 (de) | Anthracyclin-Derivate, ein mikrobiologisches Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |
Ref document number: 8006901-6 Effective date: 19920510 Format of ref document f/p: F |